RAS(ON) inhibitor daraxonrasib shows promising results in advanced pancreatic cancer
The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in patients with previously treated RAS-mutant metastatic pancreatic cancer, according to a Phase I/II first-in-human trial led by Dana-Farber Cancer Institute and across the country.
ORIGINAL SOURCE →via Medical Xpress
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · conflict
- [CONFLICT] Intermodal Asia
- [CONFLICT] UNDRR Regional Office for Arab States
- [CONFLICT] Digital security in war and conflict: challenges for civil society and tools for resilience
- [CONFLICT] Securing the Untrusted Agentic Development Layer
- [CONFLICT] KDK’dan Gazze'de "insanlık dışı muamele" raporu
- [CONFLICT] ADALET BAKANLIĞI 15 BİN PERSONEL ALIMI AÇIKLAMASI: Adalet Bakanlığı personel alımı başvuruları ne zaman? Bakan Gürlek'ten açıklama!